Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

MK-677 and Pitavastatin Interaction: Avoid | Peptide Database

Can you take MK-677 with Pitavastatin? Avoid interaction (64% confidence). See pharmacological analysis, organ load, safety flags, and dosing guidance.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Compound Profiles

MK-677

Ghrelin Receptor Agonist | Oral Growth Hormone Secretagogue

Selectively binds GHS-R1a receptors in hypothalamus and pituitary, triggering pulsatile growth hormone release while maintaining natural circadian patterns..

Pitavastatin

HMG-CoA Reductase Inhibitor | Low-Interaction Statin

Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take MK-677 with Pitavastatin?

Combining MK-677 with Pitavastatin is not recommended. Both MK-677 and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is MK-677 and Pitavastatin safe together?

This combination carries significant risk. Both MK-677 and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between MK-677 and Pitavastatin?

Both MK-677 and Pitavastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time MK-677 and Pitavastatin?

MK-677 has a half-life of ~24 hours and Pitavastatin has a half-life of ~12 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected topics

Follow this recovery question